No association between the PREP gene and lithium responsive bipolar disorder

Mamdani, Firoza; Sequeira, Adolfo; Alda, Martin; Grof, Paul; Rouleau, Guy; Turecki, Gustavo
January 2007
BMC Psychiatry;2007, Vol. 7, p1
Academic Journal
Background: Bipolar disorder (BD) is a major psychiatric condition that commonly requires prophylactic and episodic treatment. Lithium (Li) has been used for over 40 years now as an effective prophylactic agent. Response to Li treatment seems to be, at least in part, genetically determined. Although we ignore how Li specifically prevents mood episodes, it has previously been suggested that Li exerts an effect on the phosphoinositide pathway, and more recently, it has been proposed that Li may modulate prolyl endopeptidase (PREP). Methods: In this study we carried out an association study looking at the PREP gene, located on ch 6q22. Five intronic single nucleotide polymorphisms (SNP), three coding SNPs and one SNP in the 5' UTR were investigated for their frequency in a BD sample of 180 excellent Li responders, 69 Li nonresponders and 126 controls. Genotyping was carried out using the SNaPshot reaction from Applied Biosystems, which is a modified fluorescent single base pair extension procedure. Results: Following correction for multiple testing, no significant genotypic, allelic or estimated haplotypic differences were found between responders and nonresponders or between BD patients and controls. Conclusion: PREP is an interesting candidate gene to investigate in genetic studies of BD, but our findings do not support the hypothesis that genetic variation in this gene plays a major role in the etiology of BD or Li response.


Related Articles

  • Polymorphism screening and haplotype analysis of the tryptophan hydroxylase gene (TPH1) and association with bipolar affective disorder in Taiwan. Lai, Te-Jen; Wu, Chia-Yen; Tsai, Hsu-Wen; Lin, Yi-Mei J; Sun, H Sunny // BMC Medical Genetics;2005, Vol. 6, p1 

    Background: Disturbances in serotonin neurotransmission are implicated in the etiology of many psychiatric disorders, including bipolar affective disorder (BPD). The tryptophan hydroxylase gene (TPH), which codes for the enzyme catalyzing the rate-limiting step in serotonin biosynthetic pathway,...

  • Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment. Dimitrova, A.; Milanova, V.; Krastev, S.; Nikolov, I.; Toncheva, D.; Owen, M. J.; Kirov, G. // Pharmacogenomics Journal;2005, Vol. 5 Issue 1, p35 

    Lithium is the most effective mood-stabilizing drug in the therapy of bipolar affective disorder (BP). It is thought to exert its effect via the phosphatidylinositol signalling system. Myo-inositol monophosphatase 2 (IMPA2) codes for an enzyme in this system that is inhibited by lithium. It is...

  • Pharmacogenetics of Lithium Long-Term Treatment: Focus on Initiation and Adaptation Mechanisms. Serretti, Alessandro; Drago, Antonio // Neuropsychobiology;2010, Vol. 62 Issue 1, p61 

    Bipolar disorder is a common disease with a high impact in terms of personal suffering and socioeconomic burden. The disentanglement of the molecular deregulations that cause this disorder is pivotal to the understanding of its etiology. This will hopefully cast the engineering of new and more...

  • Dopamine Receptor D1 Gene –48A/G Polymorphism Is Associated with Bipolar Illness but Not with Schizophrenia in a Polish Population. Dmitrzak-Weglarz, Monika; Rybakowski, Janusz K.; Slopien, Agnieszka; Czerski, Piotr M.; Leszczynska-Rodziewicz, Anna; Kapelski, Pawel; Kaczmarkiewicz-Fass, Magdalena; Hauser, Joanna // Neuropsychobiology;2006, Vol. 53 Issue 1, p46 

    Dysregulation of dopaminergic neurotransmission has been implicated in the etiology of major psychoses. The dopamine D1 receptor (DRD1) plays a role in some brain functions and mechanisms of psychotropic drugs. Therefore, the DRD1 gene makes a good candidate gene for molecular genetic studies in...

  • [Commentary On] Need exists for genetic predictors of lithium response. Potash, James B.; Schulze, Thomas G. // Evidence Based Mental Health;Aug2014, Vol. 17 Issue 3, p72 

    The article presents a commentary on the medical study "Variant GADL1 and response to lithium therapy in bipolar I disorder" by Chen CH et al. The authors evaluate findings regarding genetic biomarkers which predict the response of patients with bipolar I disorder to therapy with lithium,...

  • Poster presentations: 1. Clinical Genetics/Counselling.  // Journal of Medical Genetics;Sep2002 Supplement, Vol. 39, pS35 

    Discusses the abstract of the research paper entitled 'Awareness of the contribution of genetic factors to aetiology amongst individuals with bipolar disorder,' by Judy Tocher and D. Craufurd and presented during the British Human Genetics Conference at the University of York in England in...

  • A Promoter Haplotype of the Inositol Monophosphatase 2 Gene (IMPA2) at 18p11.2 Confers a Possible Risk for Bipolar Disorder by Enhancing Transcription. Ohnishi, Tetsuo; Yamada, Kazuo; Ohba, Hisako; Iwayama, Yoshimi; Toyota, Tomoko; Hattori, Eiji; Inada, Toshiya; Kunugi, Hiroshi; Tatsumi, Masahiko; Ozaki, Norio; Iwata, Nakao; Sakamoto, Kaoru; Iijima, Yoshimi; Iwata, Yasuhide; Tsuchiya, Kenji J.; Sugihara, Genichi; Nanko, Shinichiro; Osumi, Noriko; Detera-Wadleigh, Sevilla D.; Kato, Tadafumi // Neuropsychopharmacology;Aug2007, Vol. 32 Issue 8, p1727 

    Lithium is an effective mood stabilizer for bipolar disorder patients and its therapeutic effect may involve inhibition of inositol monophosphatase activity. In humans, the enzyme is encoded by two genes, IMPA1 and IMPA2. IMPA2 maps to 18p11.2, a genomic interval for which evidence of linkage to...

  • Influence of an Interaction between Lithium Salts and a Functional Polymorphism in SLC1A2 on the History of Illness in Bipolar Disorder. Dallaspezia, Sara; Poletti, Sara; Lorenzi, Cristina; Pirovano, Adele; Colombo, Cristina; Benedetti, Francesco // Molecular Diagnosis & Therapy;Oct2012, Vol. 16 Issue 5, p303 

    Background: Bipolar disorder (BD) is a recurrent and disabling illness, characterized by periods of depression and mania. The history of the illness differs widely between patients, with episode frequency emerging as a strong predictor of poor illness outcome. Lithium salts are the first-choice...

  • PP2A-Bγ subunit and KCNQ2 K+ channels in bipolar disorder. Borsotto, M.; Cavarec, L.; Bouillot, M.; Romey, G.; Macciardi, F.; Delaye, A.; Nasroune, M.; Bastucci, M.; Sambucy, J-L; Luan, J-J; Charpagne, A.; Jouët, V.; Léger, R.; Lazdunski, M; Cohen, D; Chumakov, I. // Pharmacogenomics Journal;2007, Vol. 7 Issue 2, p123 

    Many bipolar affective disorder (BD) susceptibility loci have been identified but the molecular mechanisms responsible for the disease remain to be elucidated. In the locus 4p16, several candidate genes were identified but none of them was definitively shown to be associated with BD. In this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics